AzTrials
AzTrials

HealthyNCT01805999

Ispaghula and Colonic Water Content

A study testing 7 g Ispaghula in people with Healthy, run by University of Nottingham at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Chronic constipation is a phenomenon which affects nearly 20% of the population worldwide. Bulking agents such as ispaghula are used as treatments, but only half of the patients are satisfied with the treatment. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
7 g Ispaghula
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15 participants
Where
1 siteUnited Kingdom
Study dates
Mar 2013to Mar 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Apparently healthy; free from GI disorders, aged 18 and 65 years of age
  • Male or female
  • Body mass index (BMI) between 18.0 and 30.0 kg m-2
  • Suitable for MRI scanning (eg absence of metal implants, infusion pumps and pacemakers as assessed by the MRI safety questionnaire
  • No known gastrointestinal disease
  • Not currently smoking
Show all 9Show fewer
  • No strenuous exercise greater than 10 hours per week
  • No consumption of more than 21 units of alcohol in a typical week
  • No reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study.

Who cannot join

  • Inability to discontinue medication likely to alter GI transit
  • Antibiotics in the 3 weeks before the pre-study examination
  • Pre-existing condition making the need for antibiotics likely during the study
  • Previous gastrointestinal surgery (excluding cholecystectomy and appendectomy)
  • Known inflammatory bowel disease; coeliac disease
  • Subjects considered by the investigator unlikely to comply with study protocol
  • Regular (>3 times/week) use of Probiotics in the 3 weeks prior to, or during the study

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • NDD BRU and Sir Peter Mansfield Magnetic Resonance Centre

    Nottingham, Nottinghamshire, NG7 2RD

Other trials in United Kingdom

About this study

Official title: Effect of Ispaghula on Colonic Water Content

Chronic constipation is a phenomenon which affects nearly 20% of the population worldwide. Bulking agents such as ispaghula are used as treatments, but only half of the patients are satisfied with the treatment. This highlights a need for better treatment options, which requires a deeper understanding of the gastrointestinal fate of the products. The GI MRI Research group at the University of Nottingham has been developing new, non-invasive magnetic resonance imaging (MRI) techniques to image the gastrointestinal tract. In collaboration with Ironwood Pharmaceuticals, the investigators now want to understand the gastrointestinal fate of an ispaghula treatment, and also to improve the understanding of MRI parameters when they are applied to the colon.

Read the detailed description

The Rome III diagnostic criteria for constipation must include two or more of the following symptoms > 25 % of the time: straining, hard or lumpy stools, sense of incomplete evacuation, sensation of anorectal obstruction/blockage, the use of manual manoeuvres to facilitate defecation and fewer than 3 defecations per week. Treatments include osmotic laxatives such as polyethylene glycol and lactulose, stimulant laxatives such as bisacodyl, secretagogues like sodium docusate, and bulking agents such as psyllium.

A better understanding of the modes of action of these drugs is required, in order to provide better treatment for chronic constipation. This is somewhat challenging; partly because techniques available to study intestinal contents are limited, and some are unpleasant for the patients. The GI MRI group at the University of Nottingham has recently developed a non-invasive, patient friendly MRI technique for studying the colon. The technique allows assessment of colonic volumes, the response to meals, motility of the colon and transit time of ingested meals. This technique has been used to demonstrate the laxative effect of mannitol and its subsequent reversal with loperamide.

Using MRI, water provides a bright image on T2-weighted images in the small bowel, but the signal is rapidly lost once it reaches the colon. Pilot studies suggest that ispaghula; which is highly hygroscopic and can form a 1.5% gel with water, is able to maintain water in a form which produces bright images on T2-weighted scanning of the colon. The GI MRI group now want to confirm this pilot data by performing a placebo controlled trial of ispaghula husk in healthy volunteers, with the aim of further understanding the mode of action of bulking agents and further improve understanding of MRI parameters when applied to the colon. The aims will be achieved by performing a dose-finding mechanistic study in healthy volunteers, assessing their response to a test meal while taking either placebo, or 2 different doses of ispaghula. Stools will be collected, assessed for water content and compared to water content assessed from T2 weighted MRI. The studies will validate the current technique, optimise current MRI parameters and provide insights into the modes of action of ispaghula.

Conditions
Healthy
Being tested
7 g Ispaghula, 7 g placebo, 3.5g Ispaghula + 3.5 g placebo
Keywords
Ispaghula, Gastrointestinal physiology, Gastrointestinal response to sugars, MRI, gastrointestinal, stomach, small bowel, colon

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 7 g IspaghulaDietary supplement

    Also called Metamucil

  • 7 g placeboDietary supplement

  • 3.5g Ispaghula + 3.5 g placeboDietary supplement

Study groups in NCT01805999
Study groupRoleWhat they receive
7 g IspaghulaExperimentalVolunteer will take 7 g of ispaghula 3 times daily for one week
Receives: Dietary Supplement: 7 g Ispaghula
7 g placeboPlacebo comparatorVolunteer will take 7 g of a placebo 3 times a day for one week
Receives: Dietary Supplement: 7 g placebo
3.5g ispaghula + 3.5 g placeboActive comparatorVolunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
Receives: Dietary Supplement: 3.5g Ispaghula + 3.5 g placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ascending colon free water content (ACWC)

    An assessment of the volume of water in the ascending colon, as obtained from MR images

    Measured: 0 - 360 minutes

Secondary outcomes (4)
  1. Ascending, transverse and descending colon volumes

    The volumes of each region of the colon will be determined by segmenting MR images

    Measured: 0 - 360 minutes

  2. Geometric centres (GC) 24 and 48 hours

    The geometric centres of 5 transit marker pills will be determined at 24 and 48 hours after ingestion

    Measured: t = 24 hours and t = 48 hours

  3. Small bowel water content

    The volume of water in the small bowel will be evaluated from the MR images over the study day

    Measured: 0 - 360 minutes

  4. Gastric emptying

    The rate of gastric emptying throughout the study day will be determined from MR images

    Measured: 0 - 360 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2013 (estimated)
  2. Study startMar 2013
  3. Primary completionOct 2013
  4. Study completionMar 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01805999
Sponsor's protocol ID
H13122012SCS
Status last verified
Feb 2017
First submitted
5 Mar 2013
Last updated
23 Feb 2017
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing 7 g Ispaghula in people with Healthy, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ascending colon free water content (ACWC) (time frame: 0 - 360 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in